These results are derived from a global review of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
The results form the opinions of 94 UK patient groups (36 specialised in cancer; 22 in rare diseases; 16 in Parkinson's; 9 in mental health; and other specialties).
17 pharma companies are included in this 2016 UK analysis:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly (Lilly)
- Merck & Co
- Novo Nordisk
The 17 companies were chosen because a minimum of 17 UK patient groups declared familiarity with each one.
In response to a survey of pharmaceutical companies, Janssen provided information on its patient centricity and relations with patient-advocacy groups during 2016-2017 in the UK.
- How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators show the corporate reputation of individual pharma companies:
- Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Patient-group relationships (new for 2016).
- In 2016, only 25.3% of UK patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation (compared with 38% of patient groups worldwide). The 2016 result was the most negative rating from UK patient groups since 2012.
- UK patient groups were also more negative about the pharma industry’s ability to carry out a number of its main activities, notably: making high-quality, useful products; providing high-quality patient information; practising philanthropy; and providing services beyond the usual business remit (‘beyond the pill’). Moreover, only 9% of UK patient groups thought pharma “Excellent” or “Good” at fair pricing in 2016.
- On the other hand, the 94 UK patient groups were
- More positive in 2016 than patient groups from other geographic areas about other pharma industry activities, marking pharma up for the following: patient safety; integrity; patient-group partnerships; access to clinical trials; and ethical marketing.
PHARMA COMPANIES and UK PATIENT GROUPS
- The number/percentage of patient groups claiming familiarity with individual pharma companies gives an idea of each company’s corporate brand awareness within the patient community in 2016.
- 58 of 2016’s 94 respondent UK patient groups claimed familiarity with Pfizer—making the company the most well known among the respondent UK patient groups.
INDIVIDUAL COMPANY FINDINGS—UK
- Novo Nordisk ranked overall 1st for corporate reputation in 2016 among UK patient groups familiar with it. Novo Nordisk also ranked 1st for three of the seven indicators of corporate reputation measured in this analysis: patient centricity; patient safety; and integrity.
- AbbVie was ranked 1st in 2016 for two of the seven indicators of corporate reputation by UK patient groups familiar with it: provision of high-quality patient information; and patient-group partnerships.
- Teva was ranked 1st in 2016 for the provision of high-quality products by UK patient groups familiar with it (specifically by asthma, MS, and rare-disease UK patient groups).
- Janssen was ranked 1st in 2016 for transparency by UK patient groups familiar with it.
HIGHS and LOWS—UK
Pharma companies’ overall rankings—in PCRIs—among UK patient groups familiar with each company, 2016 v. 2015: ordered according to the difference between the PCRI values for the two years (high to low)
- If the UK corporate-reputation results for 2016 (17 pharma companies analysed) are compared with those of 2015 (11 pharma companies analysed) using a standardised index—the Patient Corporate Reputation Index (PCRI)—findings show the biggest jumps up the UK rankings were for:
- Merck & Co, Janssen, GSK, and Bristol-Myers Squibb—which all outperformed in 2016 their respective rankings among UK patient groups in 2015.
UK patient-group relationships with pharma.
Industry-wide findings from UK patient groups.
UK patient groups on improving corporate reputation.
Rankings of the 17 pharma companies among UK patient groups FAMILIAR with them.
Positioning of the 17 pharma companies among UK patient groups with which the companies PARTNER.
Profiles of the 17 pharma companies.
- Comments from respondent UK patient groups.
- Profile of the 94 respondent UK patient groups.
- What pharma companies were doing in patient centricity in the UK, 2016-2017: Janssen.
- Number of UK patient groups claiming familiarity with the company, 2016.
- Number of UK patient groups saying that they had a working relationship with the company, 2016.
- Company’s average score for the seven indicators of corporate reputation among UK patient groups familiar with the company, 2016 v. 2015.
- Company performance in 2015 for six indicators of corporate reputation among patient groups familiar with the company.
- Company’s scores among UK patient groups familiar with the company, and which worked with the company, for each of the seven indicators of corporate reputation, 2016.
- Company’s rankings among patient groups familiar with the company for the seven indicators of corporate reputation, 2016, familiar v. worked with, UK v. worldwide.
- Company’s overall rankings among UK patient groups familiar with the company, 2016.
- Company’s overall rankings among UK patient groups that worked with the company, 2016.
- Company’s best indicators among UK patient groups familiar with the company, 2016.
- Company’s Patient Corporate Reputation Index (PCRI), UK: 2016 v. 2015.
- Percentage of the UK patient groups that worked with the company—but which also worked with other companies, 2016.
- Performance of the company at corporate reputation in different therapy areas, compared with its own UK average for the indicators of corporate reputation, 2016.